MedTrace Logo

First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

NCT04778904 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2024-08-13

Study results available
· View outcomes & findings →

Summary

This is an open-label study to determine the safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV vaccines, with or without nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.

Conditions

Interventions

BIOLOGICAL

ChAdOx1-HBV

Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus vaccine

BIOLOGICAL

MVA-HBV

Modified Vaccinia Ankara-vectored Hepatitis B virus vaccine

BIOLOGICAL

Nivolumab

Human immunoglobulin G4 monoclonal antibody

Sponsors & Collaborators

  • Barinthus Biotherapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2023-02-24
Completion
2023-02-24

Countries

  • South Korea
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04778904 on ClinicalTrials.gov